<DOC>
	<DOC>NCT01880619</DOC>
	<brief_summary>This study will be conducted to compare the effectiveness of alpha blocker (Tamsulosin) and Anticholinergic (Solifenacin) in relieving lower urinary tract symptoms caused DJ ureteral stents.</brief_summary>
	<brief_title>Comparison of Tamsulosin and Solifenacin in Treatment of Ureteral Stent Symptoms</brief_title>
	<detailed_description>Eligible patients who signed the informed consent will randomly assigned to one of 3 groups; group 1 (control), group 2 (tamsulosin) and group 3 (Solifenacin). Ureteral stent symptom questionnaire (USSQ) will be used to compare health related quality of life scores.</detailed_description>
	<mesh_term>Tamsulosin</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<mesh_term>Cholinergic Antagonists</mesh_term>
	<criteria>Patient who will undergo unilateral ureteral stent fixation: 1. To relieve upper urinary tract obstruction caused by ureteric calculi 2. After ureteroscopic lithotripsy for ureteral calculi. 1. Patients who had LUTS before stent fixation. 2. Ureteral stent fixation after open or laparoscopic surgery. 3. Bilateral ureteral stents. 4. Patients who developed complications related to the primary endoscopic procedure 5. Patients who developed stent related complications such as hematuria, acute pyelonephritis or stent displacement</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Double J</keyword>
	<keyword>Ureteral stents</keyword>
	<keyword>Symptoms</keyword>
	<keyword>Alpha blockers</keyword>
	<keyword>Anticholinergic</keyword>
</DOC>